The humanized anti-CEA hT84.66-M5A monoclonal antibody (M5A mAb) as a radiolabeled theranostic agent is demonstrating CEA-positive tumor specificity in ongoing first-in-human PET imaging trials for colorectal cancer (NCT02293954 and NCT05245786). The gene discussed is CEACAM5; the disease is neoplasm.